Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 27;11(2):42. doi: 10.1038/s41408-021-00434-2

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — A In patients, high-risk genotypes (AA + AG) of genetic risk group A (rs884304) were associated with significantly higher day +28 serum CXCL9 levels, but not with pre-transplant CXCL9. B In luciferase reporter assays, IFN-γ activation revealed that the constructs carrying variant allele of rs884304 (P < 0.001), rs884004 (P < 0.001), and the one carrying variant alleles of all the three SNPs (P = 0.001), but not rs2869462, were associated with significantly reduced suppressive effect of CsA compared to the wild-type construct. The results were collected from three independent experiments. Luciferase activity was normalized to 1 relative to the WT and all data were plotted as the mean ± SEM. C Similar to (B), with FK506 (tacrolimus) as calcineurin inhibitor. Results were collected from three independent experiments. Luciferase activity was normalized to 1 relative to the WT and all data were plotted as the mean ± SEM. D Recovery rates of CXCL9 serum levels in patients from the lowest value post alloSCT until day 28+ in the presence of calcineurin inhibitors (slope CXCL9) was higher in the genetic high-risk group. n.s. not significant; *P ≤ 0.05; ***P < 0.001.